Survival and risk of leukemic evolution of patients classified within the proposed entity of MDS with mutated SF3B1. (A) OS of patients classified within the proposed entity of MDS with mutated SF3B1 (n = 486). (B) Cumulative incidence of AML evolution of evaluable patients (n = 52) classified within the proposed entity of MDS with mutated SF3B1. Cumulative incidence of AML evolution was estimated with a competing risk approach, considering death for any cause as a competing event.